Anacetrapib – 5 mg

Brand:
Cayman
CAS:
875446-37-0
Storage:
-20
UN-No:
Non-Hazardous - /

Anacetrapib is an inhibitor of cholesterol ester transfer protein (CETP) with IC50 values of 17 and 15 nM for CETP-dependent transfer of cholesterol esters and triglycerides, respectively.{18510} It decreases plasma levels of LDL and triglycerides, reduces atherosclerotic lesion sizes, and increases HDL levels in the E3L.CETP mouse model of atherosclerosis.{42509} Anacetrapib (150 mg/kg) increases HDL levels by 2-fold and lowers LDL and fasting plasma triglyceride levels in rhesus macaques.{42510}  

 

Out of stock

SKU: 21558 - Category:

Description

A CEPT inhibitor (IC50s = 17 and 15 nM for CETP-dependent transfer of cholesterol esters and triglycerides, respectively); decreases plasma levels of LDL and triglycerides, reduces atherosclerotic lesion sizes, and increases HDL levels in the E3L.CETP mouse model of atherosclerosis; increases HDL levels by 2-fold and lowers LDL and fasting plasma triglyceride levels in rhesus macaques at 150 mg/kg,


Formal name: (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[[4′-fluoro-2′-methoxy-5′-(1-methylethyl)-4-(trifluoromethyl)[1,1′-biphenyl]-2-yl]methyl]-4-methyl-2-oxazolidinone

Synonyms:  MK-0859

Molecular weight: 637.5

CAS: 875446-37-0

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors|Sterol Biosynthesis||Research Area|Cardiovascular System|Cardiovascular Diseases|Atherosclerosis||Research Area|Cardiovascular System|Lipids & Lipoproteins|Lipoproteins||Research Area|Cardiovascular System|Lipids & Lipoproteins|Storage & Transport